the Challenges in the Development of Hormonal Preparations for Women of a Reproductive Age

By Doris Heger-Mahn, Medical Director and Executive, Astrid Breitschaft, Sub-Investigator and Marjo Ramakers, Research Physician at dinox Clinical Research

Doris Heger-Mahn has been a Medical Director and Executive at dinox since 1999. During the previous 10 years Doris held a number of positions at Schering AG, initially specialising in the assessment of female hormonal drugs, before moving into clinical development oncology and clinical operations. Her expertise lies in the development of drugs for female health. Doris completed her medical studies at the Free University Hospital in Berlin in 1986, and became a specialist in clinical pharmacology.


Astrid Breitschaft has been a Sub-Investigator at dinox since 2003. She began her career as a physician at the Robert-Rössle hospital, which is part of the University Hospital Charité in Berlin, participating in several oncology clinical trials. Astrid is currently working on her dissertation, which evaluates the influence of blood group constellations on the duration of transfusion dependency after ABO incompatible haematopoietic stem cell transplantation. She completed her medical studies at the Free University in Berlin in 1997.


Marjo Ramakers is a registered Sexologist, and has been conducting sexological clinical trials at dinox since 2002. In 1993 she founded a sexology outpatient clinic and for the next seven years worked at the Department of Sexology and Psychosomatic Gynaecology in the Academic Medical Center in Amsterdam, where she specialised in diagnosis and treatment of vulvodynia, dyspareunia and pelvic floor dysfunction. Marjo is currently writing a treatise on new outpatient clinic sexology.